Eckert+Ziegler Q1 preview: Medical to continue growth trajectory - NuWays AG Research
Bildkälla: Stockfoto

Eckert+Ziegler Q1 preview: Medical to continue growth trajectory - NuWays AG Research

EUZ Q1 26 results are due on May 12. We expect sales of € 72.5m (+6% yoy) and adj. EBIT of € 16.0m (-1% yoy), implying a 22.1% margin (-1.7 pp yoy). This should mark a solid start to FY 26 with radiopharma continuing to drive the business.

Börsvärldens nyhetsbrev